You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)附屬擬斥最多2.1億歐元購法國生物製品開發商股權
復星醫藥(02196.HK)公布,其附屬Gland Pharma集團與賣方中法(併購)基金、Kaphy Invest、FCPE和Manxen簽訂出售選擇權協議。該出售選擇權如獲行使,Gland Pharma集團將簽訂股權購買協議,以向賣方收購目標公司Phixen societe par actions simplifiee的直接/間接股權,並向目標集團提供股東借款,涉資不逾約2.1億歐元。 建議收購交割後,Gland Pharma將直接及間接持有目標公司全部股權。目標集團於2004年於法國成立,專注於CDMO(即合同研發生產組織)業務,在無菌產品(包括高壁壘複雜制劑)、生物製品的技術開發和製造領域擁有豐富的技術積累和經驗。 公司指出,目標集團的CDMO(即合同研發生產組織)業務模式與Gland Pharma集團的長期發展規劃相契合。建議收購交割後,通過獲得歐洲本地生產基地,Gland Pharma集團將實現歐洲市場產品和服務供應能力的拓展;同時有利於提升Gland Pharma集團複雜製劑和生物製品的開發、製造及供應能力,和豐富客戶資源。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account